These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 29439294)

  • 1. Interrupted Time Series Needed to Analyze Effects of Propoxyphene Withdrawal From Market and Health Outcome Trend Estimates: Comment on the Article by Curtis et al.
    Caseja AJ; Ukken J; Froehlich M; Babary H; Lee YJ; Yoo JW
    Arthritis Rheumatol; 2018 May; 70(5):794-795. PubMed ID: 29439294
    [No Abstract]   [Full Text] [Related]  

  • 2. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.
    Larochelle MR; Zhang F; Ross-Degnan D; Wharam JF
    JAMA Intern Med; 2015 Jun; 175(6):978-87. PubMed ID: 25895077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatal poisonings involving propoxyphene before and after voluntary withdrawal from the United States' market: An analysis from the state of Florida.
    Delcher C; Chen G; Wang Y; Slavova S; Goldberger BA
    Forensic Sci Int; 2017 Nov; 280():228-232. PubMed ID: 29080523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withdrawal of propoxyphene from the US market: implications for the clinical nurse specialist.
    O'Malley P
    Clin Nurse Spec; 2011; 25(2):55-6. PubMed ID: 21311244
    [No Abstract]   [Full Text] [Related]  

  • 5. Urine drug testing of chronic pain patients. V. Prevalence of propoxyphene following its withdrawal from the United States market.
    Puet B; DePriest A; Knight J; Heltsley R; Black DL; Caplan YH; Cone EJ
    J Anal Toxicol; 2013; 37(1):1-4. PubMed ID: 23129731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A trend analysis of laboratory positive propoxyphene workplace urine drug screens before and after the product recall.
    Price J
    J Addict Med; 2015; 9(2):136-8. PubMed ID: 25622125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of propoxyphene withdrawal on opioid use in veterans.
    Hayes CJ; Hudson TJ; Phillips MM; Bursac Z; Williams JS; Austin MA; Edlund MJ; Martin BC
    Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1180-8. PubMed ID: 26248742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining product risk in context. Market withdrawal of zomepirac as a case study.
    Ross-Degnan D; Soumerai SB; Fortess EE; Gurwitz JH
    JAMA; 1993 Oct; 270(16):1937-42. PubMed ID: 8411550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Close vote by FDA advisers favors propoxyphene withdrawal.
    Traynor K
    Am J Health Syst Pharm; 2009 Mar; 66(6):518-20. PubMed ID: 19265176
    [No Abstract]   [Full Text] [Related]  

  • 10. Propoxyphene (dextropropoxyphene): a critical review of a weak opioid analgesic that should remain in antiquity.
    Barkin RL; Barkin SJ; Barkin DS
    Am J Ther; 2006; 13(6):534-42. PubMed ID: 17122535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of analgesics in France, following dextropropoxyphene withdrawal.
    Van Ganse E; Belhassen M; Ginoux M; Chrétien E; Cornu C; Ecoffey C; Aubrun F
    BMC Health Serv Res; 2018 Apr; 18(1):231. PubMed ID: 29609613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the impact of prescribing directives on opioid prescribing practices among Veterans Health Administration providers.
    Barber C; Gagnon D; Fonda J; Cho K; Hermos J; Miller M
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):40-46. PubMed ID: 27530106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Food and Drug Administration recommends against the continued use of propoxyphene.
    Food And Drug Administration Public Health Service U S Department Of Health And Human Services
    J Pain Palliat Care Pharmacother; 2011; 25(1):80-2. PubMed ID: 21426228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propoxyphene dependence and withdrawal.
    Strode SW
    Am Fam Physician; 1985 Sep; 32(3):105-8. PubMed ID: 4036770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of five analgesics for the pain of rheumatoid synovitis.
    Hardin JG; Kirk KA
    J Rheumatol; 1979; 6(4):405-12. PubMed ID: 316459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of aspirin and dextropropoxyphene-with-aspirin as analgesics in rheumatoid arthritis.
    Bedi SS
    Br J Clin Pract; 1969 Oct; 23(10):413-7. PubMed ID: 4899587
    [No Abstract]   [Full Text] [Related]  

  • 17. Dextropropoxyphene: withdrawal from the US market requested: harmful drug.
    Prescrire Int; 2009 Aug; 18(102):166-7. PubMed ID: 19746529
    [No Abstract]   [Full Text] [Related]  

  • 18. Dextropropoxyphene hydrochloride poisoning in two children.
    FRASIER SD; CRUDO FS; JOHNSON DH
    J Pediatr; 1963 Jul; 63():158-9. PubMed ID: 13959351
    [No Abstract]   [Full Text] [Related]  

  • 19. Dextro propoxyphene and the ventilatory response to carbon dioxide in man.
    BURGET DE; GREENE NM
    Yale J Biol Med; 1962 Oct; 35(2):185-8. PubMed ID: 14016991
    [No Abstract]   [Full Text] [Related]  

  • 20. It is time to remove propoxyphene from clinical practice.
    Lipman AG
    J Pain Palliat Care Pharmacother; 2009; 23(2):104-5. PubMed ID: 19492210
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.